Summary
More than 45,000 women will die of metastatic breast cancer in the United States in 1991. Endocrine therapy remains a major option for treatment of such patients, and results in complete plus partial response rates of 30% with a median duration of approximately one year. Postmenopausal status, increased age, a prolonged disease-free interval, bone and soft tissue metastases, and positive estrogen and progesterone receptors are all associated with an increased response to endocrine therapy. The use of additive hormonal therapy, specifically antiestrogens, progestins, and aromatase inhibitors, have replaced surgical ablative procedures in the majority of patients; response rates to antiestrogen therapy, progestin therapy, and aromatase inhibitors are similar, but antiestrogens have generally been associated with the most favorable therapeutic index. At present, there is no convincing evidence that either combinations of endocrine therapies or endocrine therapy combined with chemotherapy are associated with an improvement in survival for patients with metastatic disease. Future research efforts directed at defining the molecular mechanisms of endocrine activity should facilitate clinical trials of newer and potentially more effective agents. All patients with metastatic breast cancer should be considered for at least one trial of endocrine therapy provided their metastatic disease is not rapidly progressive or life-threatening.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet 2:104–107, 1896
Ingle JN: Additive hormonal therapy in women with advanced breast cancer. Cancer 53:766–777, 1984
Pritchard KI, Sutherland DJA: Diagnosis and therapy of breast cancer: The use of endocrine therapy. Hematol Oncol Clin North Am 3:765–805, 1989
Miller WR: Endocrine treatment for breast cancers: biological rationale and current progress. J Steroid Biochem Molec Biol 37:467–480, 1990
Henderson IC: Endocrine therapy of metastatic breast cancer.In Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases. Lippincott, New York, 1991, pp 559–603
Manni A: Tamoxifen therapy of metastatic breast cancer. J Clin Lab Med 109:290–299, 1987
Petru E, Schmähl D: On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer. Klinische Wochenschrift 65:959–966, 1987
Manni A, Santen RJ: Clinical use of aromatase inhibitors in the treatment of breast cancer [review]. Cancer Treat Res 39:67–81, 1988
Brodie AM, Dowsett M, Coombes RC: Aromatase inhibitors as new endocrine therapy for breast cancer [review]. Cancer Treat Res 39:51–65, 1988
Ingle JN: Principles of therapy in advanced breast cancer. Hematol Oncol Clin North Am 3:743–763, 1989
Swain SE, Lippmann ME: Endocrine therapies of cancer.In Chabner BA, Collins JM (eds) Cancer Chemotherapy: Principles and Practice. Lippincott, Philadelphia, 1990, pp 59–109
Osborne CK: Receptors.In Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases. Lippincott, Philadelphia, 1991, pp 301–325
van Netten JP, Algard FT, Coy P, Carlyle SJ, Brigden ML, Thornton KR, Peter S, Fraser T, To MP: Heterogeneous estrogen receptor levels detected via multiple microsamples from individual breast cancers. Cancer 56:2019–2024, 1985
van Netten JP, Armstrong JB, Carlyle SJ, Goodchild NL, Thornton IG, Brigden ML, Coy P, Fletcher C: Cellular distribution patterns of estrogen receptor in human breast cancer. Eur J Cancer Clin Oncol 24:1899–1901, 1988
Osborne CK: Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol 12:317–326, 1985
Iino Y, Gibson DF, Jordan VC: Antiestrogen therapy for breast cancer: current strategies and potential causes for therapeutic failure. Cancer Treat Res 53:221–237, 1991
Lippman ME, Dickson RB: Growth control of normal and malignant breast epithelium. Prog Clin Biol Res 354A:147–178, 1990
Epstein RJ: The clinical biology of hormone-responsive breast cancer. Cancer Treat Rev 15:33–51, 1988
Allegra JC, Lippman ME, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HM, Aitken SC: Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res 39: 1447–1454, 1979
Stewart JF, King RJ, Sexton SA, Millis RR, Rubens RD, Hayward JL: Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 17:449–453, 1981
Beex LVAM, Koenders AJM: Is hormonal responsiveness in breast cancer age dependent? Rev Endocrine Related Cancer 19:5–10, 1984
O'Reilly SM, Camplejohn RS, Barnes DM, Millis RR, Rubens RD, Richards MA: Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol 8:2040–2046, 1990
Osborne CK: Prognostic factors in breast cancer. Principles & Practice of Oncology: PPO Updates 4:1–11, 1990
O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA: The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63:444–446, 1991
Muss HB, Kute TE, Case LD, Smith LR, Booher C, Long R, Kammire L, Gregory B, Brockschmidt JK: The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer. Cancer 64:1894–1900, 1989
Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G, Bonadonna G: Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol 25:1165–1171, 1989
Daidone MG, Silvestrini R, Valentinis B, Persici P, Mezzanotte G, Squicciarini P, Orefice S, Salvadori B: Proliferative activity of primary breast cancer and of synchronous lymph node metastases evaluated by [3H]-thymidine labelling index. Cell Tissue Kinetics 23:401–408, 1990
Wilson AJ: Response in breast cancer to a second hormonal therapy. Rev Endocrine Rev Endocrine Related Cancer 14:5–11, 1983
Taylor SG, Gelman RS, Falkson G, Cummings FJ: Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Annals Intern Med 104:455–461, 1986
Anonymous: A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. J Clin Oncol 4:186–193, 1986
Binder SC, Flynn WJ, Pass LM: Endocrine ablative therapy of metastatic breast cancer. Ca 27:1–9, 1977
Nemoto T, Patel J, Rosner D, Dao TL: Tamoxifen (Nolvadex) versus adrenalectomy in metastatic breast cancer. Cancer 53:1333–1335, 1984
Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA: A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305:545–551, 1981
Kiang DT, Frenning DH, Vosika GJ, Kennedy BJ: Comparison of tamoxifen and hypophysectomy in breast cancer treatment. Cancer 45:1322–1325, 1980
Harvey HA, Santen RJ, Osterman J, Samojlik E, White DS, Lipton A: A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer. Cancer 43:2207–2214, 1979
Manni A: Tamoxifen therapy of metastatic breast cancer. J Lab Clin Med 109:290–299, 1987
Canney PA, Griffiths T, Latief TN, Priestman TJ: Clinical significance of tamoxifen withdrawal response [letter]. Lancet i:36, 1987
Pommier RF, Woltering EA, Keenan EJ, Fletcher WS: The mechanism of hormone-sensitive breast cancer progression on antiestrogen therapy. Implications for treatment and protocol planning. Arch Surg 122:1311–1316, 1987
Clarysse A: Hormone-induced tumor flare [editorial]. Eur J Cancer Clin Oncol 21:545–547, 1985
Plotkin D, Lechner JJ, Jung WE, Rosen PJ: Tamoxifen flare in advanced breast cancer. JAMA 240:2644–2646, 1978
Valavaara R: Phase II trials with toremifene in advanced breast cancer: a review. Breast Cancer Res Treat 16 (Suppl):S31-S35, 1990
Bellmunt J, Sole L: European early phase II dose-finding study of droloxifene in advanced breast cancer. Am J Clin Oncol 14 (Suppl 2):36–39, 1991
Witte RS, Pruitt B, Tormey DC, Moss S, Rose DP, Falkson G, Carbone PP, Ramirez G, Falkson H, Pretorius FJ: A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinologic effects. Cancer 57:34–39, 1986
Löber J, Rose C, Salimtschik M, Mouridsen HT: Treatment of advanced breast cancer with progestins. Acta Obstet Gynecol Scand (Suppl) 101:39–46, 1981
Haller DG, Glick JH: Progestational agents in advanced breast cancer: an overview. Semin Oncol 13:2–8, 1986
Pannuti F, Martoni A, Piana E, Guaraldi M: Progestins in breast cancer.In Pannuti F (ed) Hormonotherapy: Results and Perspectives. Edizioni, 1988, p. 207–222.
Sedlacek SM, Horwitz KB: The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids 44:467–483, 1991
Pannuti F, Martoni A, Di Marco AR, Piana E, Saccani F, Becchi G, Mattioli G, Barbanti F, Marra GA, Persiani W, Cacciari L, Spagnolo F, Palenzona D, Rocchetta G: Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer. Eur J Cancer 15:593–601, 1979
Della Cuna GR, Calciati A, Strada MRB, Bumma C, Campio L: High dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation. Tumori 64:143–149, 1978
Cortes Funes H, Madrigal PL, Perez Mangas G, Mendiola C: Medroxyprogesterone acetate at two different doses for the treatment of advanced breast cancer.In Campio L, Robustelli Della Cuna G, Taylor RW (eds) Role of Medroxyprogesterone in Endocrine Related Tumors. Raven Press, New York, 1983, pp 77–83
Cavalli F, Goldhirsch A, Jungi F, Martz G, Mermillod B, Alberto P: Randomized trial of low- versus highdose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 2:414–41, 1984
Gallagher CJ, Cairnduff F, Smith IE: High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer. Eur J Cancer Clin Oncol 23:1895–1900, 1987
Sedlacek SM: An overview of megestrol acetate for the treatment of advanced breast cancer. Semin Oncol 15:3–13, 1988
Tchekmedyian NS, Tait N, Abrams J, Aisner J: High-dose megestrol acetate in the treatment of advanced breast cancer. Semin Oncol 15:44–49, 1988
Muss HB, Case LD, Capizzi RL, Cooper MR, Cruz J, Jackson D, Richards F, Powell BL, Spurr CL, White D, et al: High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. J Clin Oncol 8: 1797–1805, 1990
Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA, Klijn JG: Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J Steroid Biochem Mol Biol 37:789–794, 1990
Santen RJ, Worgul TJ, Lipton A, Harvey H, Boucher A, Samojlik E, Wells SA: Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Annals Intern Med 96:94–101, 1982
Stuart-Harris RC, Smith IE: Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev 11:189–204, 1984
Wander HE, Blossey HC, Nagel GA: Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. Eur J Cancer Clin Oncol 22:1371–1374, 1986
Messeih AA, Lipton A, Santen RJ, Harvey HA, Boucher AE, Murray R, Ragaz J, Buzdar AU, Nagel GA, Henderson IC: Aminoglutethimide-induced hematologic toxicity: worldwide experience. Cancer Treat Rep 69:1003–1004, 1985
Coombes RC, Goss P, Dowsett M, Gazet JC, Brodie A: 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet ii:1237–1239, 1984
Goss PE, Powles TJ, Dowsett M, Hutchison G, Brodie AM, Gazet JC, Coombes RC: Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res 46:4823–4826, 1986
Beardwell GG, Hindley AC, Wilkinson PM, Todd IDH, Ribeiro GG, Bu'Lock D: Trilostane in the treatment of advanced breast cancer. Cancer Chemother Pharmacol 10:158–160, 1983
Coombes RC, Powles TJ, Muindi J, Hunt J, Ward M, Perez D, Neville AM: Trilostane therapy for advanced breast cancer. Cancer Treat Rep 69:351–354, 1985
Williams CJ, Barley V, Blackledge G, Hutcheon A, Kaye S, Smith D, Keen C, Webster DJ, Rowland C, Tyrrell C: Multicenter study of trilostane: a new hormonal agent in advanced postmenopausal breast cancer. Cancer Treat Rep 71:1197–1201, 1987
Sonino N: The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 317:812–818, 1987
Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, Talley RW, Potter NR: Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA 237:2079–2078, 1977
Minton MJ, Knight RK, Rubens RD, Hayward JL: Corticosteroids for elderly patients with breast cancer. Cancer 48:883–887, 1981
Bruera E, Roca E, Cedaro L, Carraro S, Chacon R: Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69:751–754, 1985
Coombes RC, Dearnaley D, Humphreys J, Gazet JC, Ford HT, Nash AG, Mashiter K, Powles TJ: Danazol treatment of advanced breast cancer. Cancer Treat Rep 64:1073–1076, 1980
Coombes RC, Perez D, Gazet JC, Ford HT, Powles TJ: Danazol treatment for advanced breast cancer. Cancer Chemother Pharmacol 10:194–195, 1983
Brodovsky HS, Holroyde CP, Laucius JF, Dugery C, Serbin J: Danazol in the treatment of women with metastatic breast cancer. Cancer Treat Rep 71:875–876, 1987
Pronzato P, Amoroso D, Ardizzoni A, Bertelli G, Conte PF, Michelotti A, Rosso R: A phase II study of danazol in metastatic breast cancer. Am J Clin Oncol 10:407–409, 1987
Perrault DJ, Logan DM, Stewart DJ, Bramwell VH, Paterson AH, Eisenhauer EA: Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs 6:207–210, 1988
Williams MR, Walker KJ, Turkes A, Blamey RW, Nicholson RI: The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53:629–636, 1986
Minton JP: The response of breast cancer patients with bone pain to L-DOPA. Cancer 33:358–363, 1974
Holtkamp W, Nagel GA: Bromocriptine in chemotherapy-resistant, metastatic breast cancer. Results of the GO-MC-BROMO 2/82 AIO Study [Ger]. Onkologie 11:121–127, 1988
Manni A, Boucher AE, Demers LM, Harvey HA, Lipton A, Simmonds MA, Bartholomew M: Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat 14:289–298, 1989
Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, Tschetter LK, Long HJ, Gerstner JG, Windschitl HE, et al: Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer 67:886–891, 1991
Kiang DT, Gay J, Goldman A, Kennedy BJ: A randomized trial of chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 313:1241–1246, 1985
Hug V, Hortobagyi GN, Drewinko B, Finders M: Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro. J Clin Oncol 3:1672–1677, 1985
Hug V, Thames H, Clark J: Chemotherapy and hormonal therapy in combination. J Clin Oncol 6:173–177, 1988
Muss HB, Smith LR, Cooper MR: Tamoxifen rechallenge: response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer. J Clin Oncol 5:1556–1558, 1987
Dorr RT, Fritz WL: Cancer Chemotherapy Handbook. Elsevier, New York, 1980
Author information
Authors and Affiliations
Additional information
Held at the 14th Annual San Antonio Breast Cancer Symposium, December 5, 1991, and supported by an educational grant from Bristol-Myers Oncology Division, Evansville IN, USA.
Rights and permissions
About this article
Cite this article
Muss, H.B. Endocrine therapy for advanced breast cancer: A review. Breast Cancer Res Tr 21, 15–26 (1992). https://doi.org/10.1007/BF01811960
Issue Date:
DOI: https://doi.org/10.1007/BF01811960